On October 7, WUXI BIO fell 3.02% in regular trading, trading at 56.05 HKD/share, with Turnover of 2.61 billion HKD.

The decline comes after a 3.16% intraday gain the previous day, indicating short-term profit-taking pressure. The broader CXO sector also traded lower, with GENSCRIPT BIO down 14.0%, INSILICO down 8.18%, XTALPI down 5.96%, PHARMARON down 3.7%, and WUXI APPTEC down 1.28%. Despite WUXI BIO's previously reported strong interim results—revenue of 11.787 billion RMB, adjusted net profit of 3.937 billion RMB, and a gross margin improvement to 46.2%—and the cancellation of 39.8245 million repurchased shares, sector-wide weakness dominated trading sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)